PubMed Health⌕ Search

Biomedical subjects

T Shuin

Publications and source records attributed to T Shuin.

At least 145 records · Page 8Linked to original sources

Enhanced expression and state of the c-myc oncogene in chemically and X-ray-transformed C3H/10T1/2 Cl 8 mouse embryo fibroblasts.

We examined expression of the c-myc oncogene in nontransformed, in three chemically transformed, and in two X-ray-transformed C3H/10T1/2 Cl 8 cell lines. In nontransformed C3H/10T1/2 cells, c-myc was expressed when cells were logarithmically growing, and expression decreased as cells reached confluence. In a methylcholanthrene-transformed cell line, MCA Si 24, c-myc expression was similar to that observed in nontransformed cells, while in two chemically transformed cell lines, Bleo Cl 2 and DMBA Cl 2, and in two radiation-transformed cell lines, F17 and F29, steady-state levels of the c-myc transcript were 5-7-fold greater than observed in nontransformed C3H/10T1/2 cells. All cell lines, both transformed and nontransformed, produced a 2.3-kilobase c-myc transcript. There was no detectable amplification or rearrangement of c-myc DNA sequences in any of the cell lines examined as determined by DNA dot blot and restriction endonuclease-Southern blotting analyses. In addition, the c-myc gene in nontransformed and transformed cell lines showed similar methylation patterns as determined by HpaII/MpsI digestion analysis, except that F19 and F29 cells lost a 0.95-kilobase HpaII band, suggesting extra region-specific methylation in these two cell lines compared to C3H/10T1/2 cells. Therefore, increased c-myc expression in the four transformed lines did not generally correlate with changes in DNA methylation in the vicinity of the c-myc gene. Our results suggest that expression of the c-myc gene is growth related and that elevated steady-state levels of c-myc RNA in certain chemically and X-ray transformed C3H/10T1/2 cell lines, such as Bleo Cl 2, DMBA Cl 2, F17, and F29, are correlated with and may participate in conversion to or maintenance of cells in the transformed state.

9,10-Dimethyl-1,2-benzanthracene↗

The enhanced 32P labeling of CDP-diacylglycerol in c-myc gene expressed human kidney cancer cells.

Correlation between c-myc gene expression and phosphatidylinositol (PI) metabolism was studied using seven human kidney cancer cell lines. We found that the exceptional incorporation of 32P into CDP-diacylglycerol (CDP-DG) was observed in only two cell lines, in which c-myc expression was increased among seven cell lines tested. In these two cell lines, PI was also labeled. The other five cell lines indicated the accumulation of radioactive PI, whereas CDP-DG was unlabeled.

Cell Division↗

Preoperative doxorubicin instillation in recurrent superficial bladder cancer.

Further recurrence of superficial bladder cancer after transurethral resection is frequent in patients who have already experienced recurrence. In an attempt to prevent or delay further recurrences in such patients, the effect of preoperative doxorubicin instillation was investigated. A total of 51 patients with recurrent superficial bladder cancer were randomized to receive either TUR alone or TUR with preoperative doxorubicin instillation. Doxorubicin was administered twice a week for 3 weeks before TUR surgery. An objective response (CR + PR) of the tumors was observed at operation in 12 of 25 (48%) evaluable doxorubicin-treated patients. Chemical cystitis was seen in 32% of the patients. Further recurrence after TUR was observed in 13 of 25 (52%) patients in the doxorubicin group, as against 15 of 23 (65%) evaluable patients in the control group. The mean disease-free interval was significantly longer (11.8 as against 7.1 months) in the doxorubicin group. These preliminary results suggest that preoperative doxorubicin instillation might be effective for prolongation of the disease-free interval in patients with recurrent bladder cancer.

Administration, Intravesical↗

Enhanced expression of c-myc and decreased expression of c-fos protooncogenes in chemically and radiation-transformed C3H/10T1/2 Cl 8 mouse embryo cell lines.

c-abl, c-fos, c-Ha-ras, c-myc, and c-mos were expressed whereas c-sis, c-fms, c-rel, c-src, and c-myb expression was not detectable in C3H/10T1/2 Cl 8 (10T1/2) cells and in eight chemically and radiation-transformed 10T1/2 cell lines. The expression of c-abl, c-fos, c-Ha-ras, and c-myc was growth-related in nontransformed 10T1/2 cells. c-abl and c-fos expression increased at confluence by 5- and 9-fold, respectively, compared to that in log phase cells. c-Ha-ras and c-myc transcripts were most abundant in log phase cells and decreased by 70 and 50%, respectively, in confluent cells. There were no significant growth-related changes in the expression of c-Ha-ras, c-myc, or c-abl in methylcholanthrene-transformed Cl 15 cells. The c-fos transcript was not detected in Cl 15 cell cultures. c-abl, c-fos, c-ras, and c-myc were expressed in whole C3H mouse embryo tissue, mouse liver, and 10T1/2 cells. Sizes of these protooncogene transcripts in 10T1/2 cells were the same as those in whole embryo tissue, except that 10T1/2 cells did not express the 8.2-kilobase abl transcript. At subconfluence, equivalent low levels of c-mos expression were observed in nontransformed and in the eight transformed 10T1/2 cell lines. The level of c-abl expression was similar in the nontransformed and in the eight transformed cell lines, but there was a new 8.2-kilobase transcript in the transformed MCA Cl 15 cell line. c-fos was expressed in 10T1/2 cells but was not detectable or greatly reduced in eight transformed cell lines. c-Ha-ras was expressed to a similar extent in eight transformed cell lines and in nontransformed 10T1/2 cells. In the UVC-4 transformed cell line, extra 3.3-kilobase Ha-ras and 7.5-kilobase Ki-ras transcripts were observed. c-myc was expressed at 4- to 7-fold higher levels in six transformed cell lines compared to 10T1/2 cells. There were no major rearrangements in or amplification of the c-myc gene in three transformed cells overexpressing this gene 5-fold. These studies show that enhanced expression of c-myc and decreased expression of c-fos correlate with the chemically and radiation transformed states of 10T1/2 cells. Changes in c-fos and c-myc oncogene expression may be casually linked to late stages of neoplastic transformation in these chemically and radiation transformed 10T1/2 cell lines.

Animals↗

[A clinical observation on urogenital tuberculosis].

A clinical observation was made on 30 cases of urogenital tuberculosis diagnosed and treated at the urological department of our Hospital between January, 1976 and December, 1984. Furthermore, 20 of them were examined for drug resistance and investigated for this tendency. They accounted for 0.23% of the outpatients. Male to female ratio was 2 to 1, but on urological tuberculosis this ratio was even. The average age was 43.7 and 50% of the patients who had a history of tuberculosis. Mycobacterium tuberculosis could be detected in 24 of the 30 cases (80%) and 18 of the 21 cases (85.4%) of urological tuberculosis. Drug resistance was examined in 20 patients. The resistant ratio of M. tuberculosis against primary drugs such as SM, PAS, INAH was low and a high resistant ratio was observed on secondary drugs such as EB, RFP, TH. These clinical observations are reported and herein discussed.

Adult↗

[Bladder cancer in patients under fifty years of age].

Fifty-five cases of carcinoma of the bladder in the age group under fifty years have been reviewed. Seventy three percent of their tumors were low grade and low stage transitional cell carcinoma. Mainly, TUR was performed on these patients and their five year relative survival rate was 97.6%. The recurrence rate after TUR was 16%.

Adult↗

[Clinical analysis of high grade bladder cancer].

The prognosis and other clinical manifestation of 128 patients with high grade bladder tumor were analyzed. Thirty two percent of the total cases of bladder cancer were high grade bladder cancer and 83% of their tumors were invasive tumor at stage T2 and worse. Urinary cytologies were positive in 88% of these patients. The 5-year survival rate in these patients was 32% and those in T1, T2 T3 and T4 cases were 64.2%, 55.6%, 22.7% and 8.0% respectively. The patients treated with radical (total) cystectomy showed a much better survival rate than the cases treated with TUR or partial cystectomy. These results suggest that high grade bladder cancers tend to be invasive and the patients with high grade bladder cancer would have a poorer prognosis than the patients with other histological grade tumors. Thus, these patients should be treated more aggressively including radical cystectomy than the other cases of bladder cancers.

Adult↗

[Treatment of low grade and low stage urinary bladder cancer].

Fifty-seven patients with low-grade and low-stage urinary bladder cancer were treated at our University Hospital between 1970 and 1980. The incidence of low grade and low stage cases was higher in the young group than in the older group, and in male than in female (p less than 0.05). Most of the patients were well-controlled by either TUR or other conservative therapies. The 5-year relative survival rate was 113%. The 5-year actual cumulative recurrence rate after TUR was 63%, whereas, the 5-year actual cumulative recurrence rate was only 35.4% in those who received intravesical instillation therapy and 25% in those who undergone RCH (Radio-Chemo-Hyperthermia) therapy. Five patients (9%) showed an increase of tumor grade from low to intermediate at the time of intravesical recurrence, but no patient showed a change from low to high grade.

Adult↗

Treatment of bladder cancer with a combination of hyperthermia, radiation and bleomycin.

The treatment of urinary bladder cancer with hyperthermia in combination with radiation and bleomycin was investigated. Immediately following a daily course of external bladder irradiation (150-200 rad; total 4 week exposure of 3500-4000 rad), patients diagnosed with transitional cell carcinoma of the bladder were irrigated with a solution of warmed saline (intravesical temperature, 42 degrees C-43 degrees C), containing 30 micrograms/ml bleomycin. Of a total of 33 patients, complete responses were observed in 14 patients, and partial responses were observed in 10. The side effects of the combined treatment were limited to local symptoms of bladder and urethral irritation. These preliminary results suggest that the combined use of hyperthermia, radiation, and bleomycin may represent an effective conservative therapy for the management of bladder cancer in humans.

Adult↗

Combination chemotherapy for metastatic urinary bladder cancer with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate.

Twenty-two patients with advanced primary bladder cancer with metastatic lesions were treated with a combination of 5-FU, vincristine, bleomycin, mitomycin, and methotrexate. Complete and partial responses were achieved in two (9%) and five (23%) patients, respectively. The overall response rate was 32%. The major toxic effects were myelosuppression and mild gastrointestinal symptoms.

Aged↗

[Intravesical instillation therapy of aclacinomycin-A (ACM) for superficial bladder tumor].

Thirty-nine patients with superficial bladder cancer underwent intravesical instillation therapy of Aclacinomycin-A (ACM). Antitumor effect of ACM was evaluated in 19 patients and objective responses (CR + PR) of tumor were observed in 84.2% of these patients. Prophylactic instillation therapy of ACM was carried out on 20 patients and the results were compared with those obtained for 10 control patients who had first episode of bladder tumor and received no instillation therapy. No significant difference in the recurrent rate was observed between these two groups. The major side effect for instillation therapy with ACM was bladder irritation which appeared in 38.5% of all the patients.

Aclarubicin↗

[The effect of intravesical chemotherapy on superficial urinary bladder cancer].

The effect of intravesical chemotherapy on superficial urinary bladder cancer was analysed. Fifty-nine patients with low-staged, low-grade bladder cancer were treated with intravesical instillation of three anticancer drugs (adriamycin, carbazilquinone and bleomycin). Complete response (CR) was observed in 15 out of 42 patients and partial response (PR) in 9 patients. Overall, a better response rate was observed with adriamycin and carbazilquinone than with bleomycin. Papillary tumors responded well to these intravesical chemotherapies compared to the non-papillary tumors . Intravesical recurrence of tumors was evaluated in 68 patients who received intravesical instillation of these three drugs after TUR of tumors. The actuarial recurrence rate of 68 patients was 11, 22 and 34% within 1, 2 and 3 years, respectively. These rates were significantly lower than that of TUR therapy alone. No serious side effect was seen in these patients. From these results, it is noted that intravesical chemotherapy is a useful approach for controlling superficial urinary bladder cancer.

Aged↗

Concentration-dependent differential effect of retinoic acid on intercellular metabolic cooperation.

A vitamin A analog, 13-cis-retinoic acid (13-cis-RA), was tested for effect on intercellular metabolic cooperation between 6-thioguanine-resistant and -sensitive V79 Chinese hamster cells. Most typical tumor promoters have been reported to inhibit metabolic cooperation. 13-cis-RA was found to enhance metabolic cooperation of cells treated with a potent tumor promoter, 12-O-tetradecanoyl-phorbol-13-acetate. However, inhibition of metabolic cooperation was noticed when 13-cis-RA was used at higher concentrations.

Animals↗

Studies on the cytotoxicity, mutagenicity and chromosomal aberration-inducing activity of aclacinomycin A in cultured mammalian cells.

The cytotoxicity mutagenicity and chromosomal aberration-inducing activity of aclacinomycin A were studied using cultured mammalian cells. Aclacinomycin A was found to be a potent inhibitor of RNA synthesis in HeLa S3 cells. The survival curve in the presence of aclacinomycin A exhibited a concentration- and time-dependent cytocidal effect, and showed a sigmoidal shoulder. A cytofluorometric study suggested that aclacinomycin A caused a temporary blockage of cell cycle progression. In mutation assay using V79 cells, aclacinomycin A was shown to induce 8-azaguanine-resistant mutation, being several times more mutagenic than adriamycin. The induction of chromosomal aberrations by aclacinomycin A was also demonstrated. When cells from various sources were treated with aclacinomycin A, they were affected at a similar concentration with the exception of human normal fibroblasts, which were a little less sensitive than the others.

Aclarubicin↗